Method for destroying hyperproliferative cells by combined p53 and taxoid treatment

Abstract

A medicinal combination of one or more nucleic acids that at least partially inhibit oncogenic cell signalling pathways, and a therapeutic anticancer agent, for use simultaneous, separate or over a period of time to treat hyperproliferative diseases.

1 . Medicinal combination of one or more nucleic acids that at least partially inhibit the oncogenic cell signalling pathways and an anticancer therapeutic agent, for use simultaneously, separately or spread over time for the treatment of hyperproliferative pathologies.  
     
     
         2 . Combination according to    claim 1   , characterized in that the nucleic acid is a deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) coding for a product that at least partially inhibits the oncogenic cell signalling pathways.  
     
     
         3 . Combination according to    claim 2   , characterized in that the nucleic acid is a DNA coding for an antisense RNA.  
     
     
         4 . Combination according to    claim 2   , characterized in that the nucleic acid is a DNA coding for a ligand RNA.  
     
     
         5 . Combination according to    claim 2   , characterized in that the nucleic acid is a DNA coding for a dominant negative.  
     
     
         6 . Combination according to    claim 2   , characterized in that the nucleic acid is a DNA coding for an ScFv.  
     
     
         7 . Combination according to    claim 2   , characterized in that the nucleic acid is a DNA coding for a tumour suppressor protein.  
     
     
         8 . Combination according to    claim 1   , characterized in that the nucleic acid is an antisense oligonucleotide, where appropriate chemically modified.  
     
     
         9 . Combination according to one of the preceding claims, characterized in that the nucleic acid is incorporated in a vector.  
     
     
         10 . Combination according to    claim 9   , characterized in that the vector is chosen from liposome, nanoparticle, peptide complex, cationic lipids and lipopolyamines.  
     
     
         11 . Combination according to    claim 9   , characterized in that the vector is a viral vector derived from retroviruses, adenovirus, herpesvirus, AAV or vaccinia virus.  
     
     
         12 . Combination according to one of the preceding claims, characterized in that the nucleic acid is administered directly at the site to be treated.  
     
     
         13 . Combination according to    claim 1   , characterized in that the anticancer therapeutic agent is a chemotherapeutic agent chosen from cisplatin, taxoids, etoposide, TNF, adriamycin, camptothecin, vinca alkaloids and navellein.  
     
     
         14 . Combination according to    claim 13   , characterized in that the anticancer chemotherapeutic agent is a taxoid.  
     
     
         15 . Combination according to    claim 14   , characterized in that the anticancer chemotherapeutic agent is chosen from taxol, docetaxel and paclitaxel.  
     
     
         16 . Combination according to one of    claims 13    to    15   , characterized in that the anticancer chemotherapeutic agent is administered parenterally.  
     
     
         17 . Combination according to one of the preceding claims, characterized in that the nucleic acid and the anticancer chemotherapeutic agent are used simultaneously.  
     
     
         18 . Combination according to one of    claims 1    to    16   , characterized in that the nucleic acid is administered before the anticancer chemotherapeutic agent.  
     
     
         19 . Medicinal combination of one or more tumour suppressor genes and a taxoid, for use simultaneously, separately or spread over time for the treatment of hyperproliferative pathologies.  
     
     
         20 . Combination according to    claim 19   , characterized in that the suppressor gene codes for the wild-type form of the p53 protein.  
     
     
         21 . Combination according to    claim 19   , characterized in that the suppressor gene codes for the waf1 protein.  
     
     
         22 . Combination between    claim 1   , characterized in that the anticancer therapeutic agent is a radiotherapeutic agent.  
     
     
         23 . A method of treatment of hyperproliferative pathologies comprising administering a combination of (a) a nucleic acid that at least partially inhibits an oncogenic cell signalling pathway, and (b) an anticancer therapeutic agent; wherein the nucleic acid and the anticancer agent are used simultaneously, separately or spread over time.  
     
     
         24 . The method according to    claim 23   , wherein the nucleic acid is a deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) coding for a product that at least partially inhibits the oncogenic cell signalling pathways.  
     
     
         25 . The method according to    claim 24   , wherein the nucleic acid is a DNA coding for an antisense RNA.  
     
     
         26 . The method according to    claim 24   , wherein the nucleic acid is a DNA-coding for a ligand RNA.  
     
     
         27 . The method according to    claim 24   , wherein the nucleic acid is a DNA coding for a dominant negative protein.  
     
     
         28 . The method according to    claim 24   , wherein the nucleic acid is a DNA coding for a single chain Fv antibody (ScFv).  
     
     
         29 . The method according to    claim 24   , wherein the nucleic acid is a DNA coding for a tumour suppressor protein.  
     
     
         30 . The method according to    claim 23   , wherein the nucleic acid is an antisense oligonucleotide.  
     
     
         31 . The method according to    claim 24   , wherein the nucleic acid is incorporated in a vector.  
     
     
         32 . The method according to    claim 31   , wherein the vector is prepared with a compound selected from the group consisting of liposomes, nanoparticles, peptide complexes, cationic lipids, and lipopolyamines.  
     
     
         33 . The method according to    claim 31   , wherein the vector is a viral vector selected from the group consisting of retrovirus, adenovirus, herpesvirus, adeno-associated virus, or vaccinia virus.  
     
     
         34 . The method according to    claim 23   , wherein the nucleic acid is administered directly to the site to be treated.  
     
     
         35 . The method according to    claim 23   , wherein the anticancer therapeutic agent is a chemotherapeutic agent selected from the group consisting of cisplatin, taxoids, etoposide, tumor necrosis factor (TNF), adriamycin, camptothecin, vinca alkaloids, and navellein.  
     
     
         36 . The method according to    claim 35   , wherein the anticancer chemotherapeutic agent is a taxoid.  
     
     
         37 . The method according to    claim 36   , wherein the taxoid anticancer chemotherapeutic agent is selected from the group consisting of taxol, docetaxel, and paclitaxel.  
     
     
         38 . The method according to    claim 23   , wherein the anticancer chemotherapeutic agent is administered parenterally.  
     
     
         39 . The method according to    claim 23   , wherein the nucleic acid and the anticancer chemotherapeutic agent are used simultaneously.  
     
     
         40 . The method according to    claim 23   , wherein the nucleic acid is administered before the anticancer chemotherapeutic agent.  
     
     
         41 . A method for treatment of hyperproliferative pathologies comprising administering a combination of a tumor suppressor gene and a taxoid simultaneously, separately, or spread over time.  
     
     
         42 . The method according to    claim 41   , wherein the tumor suppressor gene codes for the wild-type form of p53 protein.  
     
     
         43 . The method according to    claim 41   , wherein the tumor suppressor gene codes for waf1 protein.  
     
     
         44 . The method according to    claim 23   , wherein the anticancer therapeutic agent is a radiotherapeutic agent.